Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Summary

This study will assess the efficacy and safety of AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)

Timeline

Start

2011-11

Primary completion

2012-09

Completion

2012-09

Outcome

Missed primary endpoint

paper Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment. PMID 27214258 ↗

Publications

• Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A. Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies. Mov Disord. 2016 Jul;31(7):1054-8. doi: 10.1002/mds.26585. Epub 2016 May 23.

Drugs

Indications